219 related articles for article (PubMed ID: 9103545)
1. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
Lim HJ; Masin D; Madden TD; Bally MB
J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
[TBL] [Abstract][Full Text] [Related]
2. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
[TBL] [Abstract][Full Text] [Related]
3. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.
Lim HJ; Parr MJ; Masin D; McIntosh NL; Madden TD; Zhang G; Johnstone S; Bally MB
Clin Cancer Res; 2000 Nov; 6(11):4449-60. PubMed ID: 11106266
[TBL] [Abstract][Full Text] [Related]
4. Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.
Cui J; Li C; Wang L; Wang C; Yang H; Li Y; Zhang L; Zhang L; Guo W; Liang M
Int J Pharm; 2009 Feb; 368(1-2):24-30. PubMed ID: 18973800
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
[TBL] [Abstract][Full Text] [Related]
6. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
[TBL] [Abstract][Full Text] [Related]
7. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
[TBL] [Abstract][Full Text] [Related]
8. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
Li C; Cui J; Wang C; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Int J Pharm; 2008 Oct; 362(1-2):60-6. PubMed ID: 18598745
[TBL] [Abstract][Full Text] [Related]
9. Liposomal drugs dispersed in hydrogels. Effect of liposome, drug and gel properties on drug release kinetics.
Mourtas S; Fotopoulou S; Duraj S; Sfika V; Tsakiroglou C; Antimisiaris SG
Colloids Surf B Biointerfaces; 2007 Apr; 55(2):212-21. PubMed ID: 17223020
[TBL] [Abstract][Full Text] [Related]
10. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
[TBL] [Abstract][Full Text] [Related]
11. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
Reszka R; Beck P; Fichtner I; Hentschel M; Richter J; Kreuter J
J Pharmacol Exp Ther; 1997 Jan; 280(1):232-7. PubMed ID: 8996201
[TBL] [Abstract][Full Text] [Related]
12. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
13. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
15. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice.
Chang CW; Barber L; Ouyang C; Masin D; Bally MB; Madden TD
Br J Cancer; 1997; 75(2):169-77. PubMed ID: 9010021
[TBL] [Abstract][Full Text] [Related]
16. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
[TBL] [Abstract][Full Text] [Related]
17. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
[TBL] [Abstract][Full Text] [Related]
18. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
Genne P; Olsson NO; Gutierrez G; Duchamp O; Chauffert B
Anticancer Drug Des; 1994 Apr; 9(2):73-84. PubMed ID: 8166930
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
[TBL] [Abstract][Full Text] [Related]
20. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
